Juan Carlos Varela, MD, PhD

Board-Certified Hematologist and Internal Medicine Physician

Bone marrow transplant specialist who focuses on immunotherapy for leukemia, lymphoma and multiple myeloma
Juan Carlos Varela, MD, PhD

Juan Carlos Varela, MD, PhD obtained his MD/PhD from the Medical University of South Carolina in 2010. He received his residency training in internal medicine in the Osler medical training program at the Johns Hopkins Hospital. Subsequently, he completed his fellowship training in hematology at the Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. His clinical interests include novel immune therapies for hematological malignancies and bone marrow transplantation, and treatments for leukemia, lymphoma and multiple myeloma. Dr. Varela is an award-winning researcher and physician, having been honored as a Calebresi Scholar and an Abney Scholar at the Medical University of South Carolina in recognition of clinical excellence.

Dr. Varela is a member of the American Society for Blood and Marrow Transplantation and the American Society of Hematology. He is the principal investigator for numerous national clinical trials. Dr. Varela's person and professional philosophy is to treat the patient, not the disease. He is passionate about providing support to his patient and their families and caregivers.

Specialties

  • Immunotherapy
  • Hematology
  • Bone Marrow Transplantation
  • Oncology
  • Leukemia
  • Lymphoma
  • Multiple Myeloma

Research

  • Clinical Trials
  • Ongoing Research

Publications

  • Neal L, Bailey S, Wyatt M, Bowers J, Majchrzak K, Nelson M, Haupt C, Paulos C, Varela JC. The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies. Journal of Immunology Research and Therapy. In Press, 2017.
  • Majchrzak K, Nelson M, Bowers J, Bailey S, Meek, M, Wrangle J, Varela JC, Rubinstein M, Li Z, Himes R, Chan S, Paulos C. β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. JCI Insight. 20; 2(8) 2017.
  • Shütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP. Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget, Epub ahead of print, 2016.
  • Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Paseman S, Mackensen A, Oelke M, Schneck JP, Schütz C. CD47 enhances in vivo functionality of artificial antigen presenting cells. Clin Can Res, 1;21(9):2075-83, 2015.
  • Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J, 29;6(1), 2015.

Points of Difference

  • Accredited by Foundation for the Accreditation of Cellular Therapy (FACT) 2009-Present
  • Center for Excellence Distinction on all available Insurance Companies
  • Accredited by National Marrow Donor Program (NMDP)
  • Involved in the Cancer and Leukemia Group B (CALGB)
  • Clinical Trials Offered

 

Results & Outcomes

  • Clinical Trials
  • Donor-Provided Bone Marrow Transplantation Survival Rate (substantially higher than the national average)
  • Ongoing Research Projects
(407) 303-2070